 Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover design to evaluate and compare the relative bioavailability and therefore the bioequivalence of three doses 400 mg, 600 mg and 800 mg of eslicarbazepine acetate for two formulations CTF versus TBM after a single oral dose administration under fasting conditions 